Novartis RNA pullback gives biotech stocks whiplash
This article was originally published in Scrip
Novartis stopped short of saying it has given up on RNA therapeutics entirely, but the company's pullback from the sector hurt several public biotechnology firms whose stocks declined in the US based on statements from the Swiss drug maker.
You may also be interested in...
The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.